Scipio bioscience appoints new CEO to usher the next development phases.
Scipio bioscience is pleased to announce that our board of directors has nominated Pierre CHAUMAT, who previously held the position of VP Chief Manufacturing Officer, as the new CEO of Scipio bioscience. The decision has been taken to further support Scipio bioscience in its evolution towards new markets and the expansion of its range of novel single-cell applications.
Scipio bioscience’s Single-cell Grant Program is now open for applications!
Scipio bioscience is welcoming applications for single-cell projects to be rewarded with benchtop kits, sequencing, and access to the data analysis software to generate exciting new data in the single-cell world.
Single-cell skin samples prepared with Asteria™ and analysed with Cytonaut™ win ESDR 2022 Poster Prize
The European Society for Dermatological Research conference awarded the outcome of the collaboration between Scipio bioscience and the Saint Louis institute with a prize at their 2022 annual conference.
Scipio bioscience’s first single-cell webinar on Sept 29th, 2022
We are glad to open the registration to our first webinar on Sept 29th, 11am CEST, to showcase the sample preparation and data analysis workflow of the Asteria™ single-cell RNA sequencing kit and Cytonaut™ analysis software respectively!
Scipio bioscience RevGel-seq Technology in pre-print publication!
The first publication on our reversible hydrogel technology is available in pre-print!
Scipio bioscience selected for €2.5M European Innovation Council grant
The European Innovation Council just announced that Scipio bioscience is one of the select few to receive grant funding and future investment as part of the EIC accelerator program. This additional funding will speed up the development of the next generation of our single-cell technology.